Fleebs-Logo
Details werden geladen...

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia | The Manila Times

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p

Ähnliche Seiten

https://www.manilatimes.net/2026/06/06/tmt-newswire/globenewswire/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-phase-2b-access-program-of-aleniglipron-for-obesity/2359859

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity | The Manila Times

https://www.manilatimes.net/2026/06/06/tmt-newswire/globenewswire/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-phase-2b-access-program-of-aleniglipron-for-obesity/2359859
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/zenas-biopharma-announces-data-from-the-registrational-phase-3-indigo-trial-of-obexelimab-in-immunoglobulin-g4-related-disease-igg4-rd-simultaneously-presented-at-the-eular-2026-congress-and-published-in-the-new-england-journal-of-medicine/2357388

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Publi...

https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/zenas-biopharma-announces-data-from-the-registrational-phase-3-indigo-trial-of-obexelimab-in-immunoglobulin-g4-related-disease-igg4-rd-simultaneously-presented-at-the-eular-2026-congress-and-published-in-the-new-england-journal-of-medicine/2357388
https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/revolution-medicines-announces-asco-plenary-presentation-highlighting-unprecedented-results-from-pivotal-phase-3-rasolute-302-clinical-trial-of-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer/2355204

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreati...

https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/revolution-medicines-announces-asco-plenary-presentation-highlighting-unprecedented-results-from-pivotal-phase-3-rasolute-302-clinical-trial-of-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer/2355204
https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/dianthus-therapeutics-announces-initiation-of-phase-3-emerge-trial-of-claseprubart-in-generalized-myasthenia-gravis/2374736

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis | The Manila Times

https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/dianthus-therapeutics-announces-initiation-of-phase-3-emerge-trial-of-claseprubart-in-generalized-myasthenia-gravis/2374736
https://www.manilatimes.net/2026/06/04/tmt-newswire/globenewswire/gh-research-announces-publication-of-phase-2a-postpartum-depression-results/2358652

GH Research Announces Publication of Phase 2a Postpartum Depression Results | The Manila Times

https://www.manilatimes.net/2026/06/04/tmt-newswire/globenewswire/gh-research-announces-publication-of-phase-2a-postpartum-depression-results/2358652
https://www.manilatimes.net/2026/06/01/tmt-newswire/globenewswire/ucb-and-biogen-announce-publication-in-the-lancet-of-positive-dapirolizumab-pegol-dzp-phase-3-study-results-in-systemic-lupus-erythematosus/2355391

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus | The Manila Times

https://www.manilatimes.net/2026/06/01/tmt-newswire/globenewswire/ucb-and-biogen-announce-publication-in-the-lancet-of-positive-dapirolizumab-pegol-dzp-phase-3-study-results-in-systemic-lupus-erythematosus/2355391